TELA Bio, Inc. Files 8-K Report
Ticker: TELA · Form: 8-K · Filed: Apr 15, 2024 · CIK: 1561921
| Field | Detail |
|---|---|
| Company | Tela Bio, Inc. (TELA) |
| Form Type | 8-K |
| Filed Date | Apr 15, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, financial-reporting
TL;DR
TELA Bio filed an 8-K, mostly financial exhibits. Nothing major new.
AI Summary
On April 15, 2024, TELA Bio, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating updates or disclosures related to the company's financial health and operations. No specific new events or material changes were detailed in the provided excerpt.
Why It Matters
This filing provides an official record of TELA Bio's financial disclosures and exhibits, which are important for investors to assess the company's financial standing and operational status.
Risk Assessment
Risk Level: low — The filing is a routine 8-K report primarily containing financial statements and exhibits, with no immediate indication of significant new risks or events.
Key Players & Entities
- TELA Bio, Inc. (company) — Registrant
- April 15, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 001-39130 (company_id) — Commission File Number
- 45-5320061 (company_id) — I.R.S. Employer Identification No.
- 1 Great Valley Parkway, Suite 24 (address) — Principal executive offices street
- Malvern (city) — Principal executive offices city
- Pennsylvania (state) — Principal executive offices state
- 19355 (zip_code) — Principal executive offices zip code
- 484-320-2930 (phone_number) — Registrant's telephone number
FAQ
What is the primary purpose of this 8-K filing for TELA Bio, Inc.?
The primary purpose of this 8-K filing is to report on 'Other Events' and 'Financial Statements and Exhibits' as of April 15, 2024.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on April 15, 2024.
In which state is TELA Bio, Inc. incorporated?
TELA Bio, Inc. is incorporated in Delaware.
What is TELA Bio, Inc.'s principal executive office address?
TELA Bio, Inc.'s principal executive office is located at 1 Great Valley Parkway, Suite 24, Malvern, Pennsylvania, 19355.
What is the telephone number for TELA Bio, Inc.?
The telephone number for TELA Bio, Inc. is (484) 320-2930.
Filing Stats: 441 words · 2 min read · ~1 pages · Grade level 9.7 · Accepted 2024-04-15 07:13:10
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share TELA Nasdaq Global Market
Filing Documents
- tm2411582d1_8k.htm (8-K) — 25KB
- tm2411582d1_ex99-1.htm (EX-99.1) — 14KB
- tm2411582d1_ex99-1img001.jpg (GRAPHIC) — 6KB
- 0001104659-24-046970.txt ( ) — 223KB
- tela-20240415.xsd (EX-101.SCH) — 3KB
- tela-20240415_lab.xml (EX-101.LAB) — 33KB
- tela-20240415_pre.xml (EX-101.PRE) — 22KB
- tm2411582d1_8k_htm.xml (XML) — 4KB
01
Item 8.01 Other Events. On April 15, 2024, TELA Bio, Inc. issued a press release announcing the U.S. commercial launch of OviTex IHR (Inguinal Hernia Repair) Reinforced Tissue Matrix. A copy of this press release is filed as Exhibit 99.1 hereto and incorporated herein by reference.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits The following exhibits are being filed herewith: Exhibit No. Document 99.1 Press Release of TELA Bio, Inc., dated April 15, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TELA BIO, INC. By: /s/ Antony Koblish Name: Antony Koblish Title: President, Chief Executive Officer and Director Date: April 15, 2024